Open AccessBook
Myasthenia Gravis
Huub Oosterhuis
- 01 Jan 1997
2.4K
About: The article was published on 01 Jan 1997. and is currently open access. The article focuses on the topics: Myasthenia gravis & Ocular myasthenia.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
The role of thymomas in the development of myasthenia gravis.
TL;DR: Significant associations between different thymic alterations and clinical findings are discussed and peculiarities in thymoma‐associated myasthenia gravis are highlighted.
65
Therapeutic Approaches to Ion Channel Diseases
Diana Conte Camerino,Jean-François Desaphy,Domenico Tricarico,Sabata Pierno,Antonella Liantonio +4 more
TL;DR: Among the newest aspect of ion channel pharmacology, it is drawn attention to how polymorphisms or mutations in ion channel genes may modify sensitivity to drugs, opening the way toward the development of pharmacogenetics.
65
Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001
TL;DR: Patients with MG dying between 1951 and 1995 had a higher occurrence of respiratory tract disease listed as cause of death than had a matched control group, and the lack of difference after 1995 probably reflects improved treatment of MG and its complications.
Increasing incidence of elderly onset patients with myasthenia gravis in a local area of Japan.
Naoko Matsui,S. Nakane,Y. Nakagawa,Kazuya Kondo,Takao Mitsui,Toshio Matsumoto,Kokichi Arisawa,Ryuji Kaji +7 more
TL;DR: The increasing incidence of elderly onsetMG in Japanese patients similar to that reported in Caucasians has been confirmed and the clinical features suggest different immunological backgrounds between young onset and elderly onset MG patients, irrespective of the ethnic background.
64
Survivin in autoimmune diseases.
G. Gravina,C. Wasen,Maria-Jose Garcia-Bonete,Minna Turkkila,Malin C. Erlandsson,Malin C. Erlandsson,S. Töyrä Silfverswärd,Mikael Brisslert,Rille Pullerits,Rille Pullerits,Karin M. E. Andersson,Gergely Katona,Maria Bokarewa,Maria Bokarewa +13 more
TL;DR: This review summarises the knowledge about non-malignant properties of survivin and focuses on its engagement in cellular and molecular pathology of autoimmune diseases, and highlights utility ofsurvivin measures for clinical applications.
64